

Permanent J-Code for ELZONRIS[®] (tagraxofusp-erzs) Injection for Intravenous (IV) Use, effective October 1, 2019

ELZONRIS INJECTION FOR	IV USE	
Permanent J-Code ¹ : J9269 Injection, tagraxofusp-erzs, 10 mcg	Revenue Code ³ : 0636	CPT Codes ⁴ : 96413 or 96409

The information contained in this guide is intended to provide a general understanding of the coding and billing process and is not intended to assist healthcare providers in obtaining reimbursement for any specific claim. This guide is for informational purposes only and does not represent legal or billing advice. The content here is based on information as of October 1, 2019 and is subject to change.

Please see accompanying full Prescribing Information, including Boxed WARNING.



This guide is designed to help healthcare providers, hospital staff, and coding and billing managers by providing information on coding and billing for ELZONRIS Injection for IV Use, in the hospital settings for all insurance types, including Medicare, Medicare Advantage, Medicaid, and commercial payers.

FIND IN THIS GUIDE

- Coding and billing overview, processing a claim, overview of codes (NDC, ICD-10-CM, CPT, and HCPCS)
- · Payer specifics: Medicare, Medicare Advantage, Medicaid, commercial payers
- Stemline ARC[®]
- Appendix:
- Sample annotated physician office billing CMS-1500
- Sample annotated hospital outpatient billing CMS-1450/UB-04
- Summary of billing codes

SUMMARY OF CODING AND BILLING FOR ELZONRIS INJECTION FOR IV USE

DISPENSING PACK QUANTITY	1 vial/box
NDC	72187-0401-1 or 72187-0401-01
PERMANENT J-CODE	J9269 Injection, tagraxofusp-erzs, 10 mcg
CPT CODES⁴	96413 or 96409
DESCRIPTION ⁵	Single-dose, sterile glass vial containing 1 mL of solution

ELZONRIS Injection for IV Use J-Code effective October 1, 2019.

CODING AND BILLING FOR ELZONRIS INJECTION FOR IV USE

Processing a claim

To process a claim, it is important to:

- Complete the correct form (CMS-1500, CMS-1450/UB-04)
- Include correct codes: NDC, ICD-10-CM, CPT, and HCPCS
- 🗹 Ensure all patient information (name, address, insurance ID number) is accurate
- Verify the name of the healthcare provider and National Provider Identifier (NPI)
- 🕑 Use the most appropriate ICD-10-CM diagnosis and CPT procedure codes associated with each patient's diagnosis and care
- Specify the setting or place of service (POS) where the infusion was provided (eg, hospital setting) and dose given (10-mcg increments)
- Sensure patient medical records contain documentation that supports the diagnosis and procedure codes submitted on the claim
- 🕑 Complete all claim form fields accurately and provide information upon request

Overview of codes

Correct coding is essential for timely claims processing and reimbursement. Important codes include the following:

National Drug Codes (NDCs)⁶

Injection for IV Use to an 11-digit NDC requires the use of a leading zero in the product code.

International Classification of Disease, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis code⁷ when submitting a claim for the item or service.

Healthcare Common Procedure Coding System (HCPCS) codes^{8,9} provided by a physician.

NDCs⁶

ELZONRIS Injection for IV Use NDC numbers are listed below. Please note that converting the 10-digit NDC to an 11-digit NDC requires the use of a leading zero in the product code.

ELZONRIS INJECTION FOR IV USE PACKAGE SIZE	NDC	FORMS
2.25 in. × 2 in.	10-digit: 72187-0401-1	CMS-1500; CMS-1450/UB-04
2.25 11. × 2 11.	11-digit: 72187-0401-01	CMS-1500; UB-04

Always confirm coding requirements with each patient's individual health plan, as the information required may vary.

- Once you have administered ELZONRIS Injection for IV Use to your patient, you may submit a claim to the patient's health plan.
 - NDCs help healthcare providers and health plans identify specific product package sizes. Some health plans require healthcare providers to use an 11-digit NDC when reporting a drug on a claim form. Converting the 10-digit NDC for ELZONRIS
 - Use the current ICD-10-CM codes to report a patient's diagnosis on claim submissions. Be sure to use the correct coding

Most health plans cover IV therapies under their medical benefit. CPT codes are used to identify services and procedures



CODING AND BILLING OVERVIEW (cont'd)

ICD-10-CM diagnosis codes

It's important to check with the health plan to verify coding and special billing requirements. The ICD-10-CM diagnosis code for ELZONRIS Injection for IV Use is shown below.

The ICD-10-CM diagnosis code for ELZONRIS Injection for IV Use¹⁰

ICD-10-CM	DESCRIPTION	FO	RMS
	DESCRIPTION	CMS-1500	CMS-1450 (UB-04)
C86.4	Blastic NK-cell lymphoma Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	ltem 21	Form Locator 67

HCPCS codes^{8,9}

Most health plans cover IV therapies under their medical benefit. CPT codes are used to identify services and procedures provided by a physician.

HCPCS LEVEL I CODES ^{5,6}		DESCRIPTION	FORMS		
	ODES"	IV	CMS-1500	CMS-1450/UB-04	
CPT Code	96413	Chemotherapy administration, IV infusion technique, up to 1 hour, single or initial substance/drug	ltem 24D	Form Locator 44	
CFTCOde	96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	item 24D	FOITH LOCALOF 44	
Revenue Code	0636	Drugs requiring detailed coding	N/A	Form Locators 42 and 43	
PERMANENT J-C	ODE ¹				
J926	9	ELZONRIS Injection, tagraxofusp-erzs, 10 mcg	N/A	Form Locator 44 or electronic comment field	

PAYER SPECIFICS

Medicare

Medicare Part B¹¹

ELZONRIS Injection for IV Use is covered by Medicare Part B in the outpatient setting.

Medicare Administrative Contractors (MACs)¹²

MACs are multistate regional contractors responsible for administering both Medicare Part A and Medicare Part B claims. MACs are the central point of contact for providers of healthcare services. MACs are the primary operational contact between the Medicare fee-for-service (FFS) program and the healthcare providers enrolled in the program.

To find your Medicare Part B or durable medical equipment (DME) MAC jurisdiction, visit the CMS website.

Medicare Part D¹¹

As an infused drug, ELZONRIS Injection for IV Use is not covered under Medicare Part D benefit.

Medicaid

ELZONRIS Injection for IV Use may be available under state Medicaid programs. Each state Medicaid program has its own eligibility standards, so coverage will vary from state to state. It's important to understand how your patient's Medicaid coverage works by contacting the Medicaid program or accessing the specific coverage information. Some Medicaid plans require prior authorization.

Commercial Health Plans⁷

Commercial health plans may provide coverage for ELZONRIS Injection for IV Use under the pharmacy or medical benefit. While commercial health plans may provide coverage under either of these benefits, the medical benefit will be utilized for the majority of plans. Please contact your patient's health plan for further guidance. Specific coverage requirements and restrictions depend on a given patient's benefits and may vary by plan type and site of service.

References: 1. Centers for Medicare & Medicaid Services. C-Codes Effective October 1, 2019. Available at https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/ HCPCS-Quarterly-Update.html. Accessed September 5, 2019. 2. Centers for Medicare & Medicaid Services. Fiscal year 2020 final rule. Available at https://www.cms.gov/ Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page-Items/FY2020-IPPS-Final-Rule-Data-Files.html. Accessed August 26, 2019. 3. MLN Matters article index 2017 through August 2018. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/2017-2018MLNMattersArticlesIndex.pdf. Accessed October 15, 2018. 4. Optim360. 2018 Colling Companion for Oncology/ Hematology. Eden Prairie, MN: Optim360; 2017. 5. ELZONRIS [prescribing information]. New York, NY, US: Stemline Therapeutics, Inc.; December 2018. 6. National Drug Code database background information. US Food & Drug Administration website. https://www.fda.gov/drugs/developmentapprovalprocess/ucm070829.htm. Updated March 20, 2017. Accessed October 8, 2018. **7.** ICD-10-CK, ICD-10-PCS, CPT, and HCPCS code sets. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/ICD9-10CM-ICD10PCS-CPT-HCPCS-Code-Sets-Educational-Tool-ICN900943.pdf Published May 2018. Accessed October 8, 2018. 8. Einodshofer MT, Duren LN. Cost management through care management, part 2: the importance of managing specialty drug utilization in the medical benefit. Am Health Drug Benefits. 2012;5(6):359-364. 9. HCPCS coding questions. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Medicare/ Coding/MedHCPCSGenInfo/HCPCS_Coding_Questions.html. Updated July 22, 2013. Accessed October 9, 2018. 10. 2018 ICD-10 CM and GEMs. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Medicare/Coding/ICD10/2018-ICD-10-CM-and-GEMs.html. Updated August 11, 2018. Accessed October 8, 2018. 11. Medicare drug coverage under Medicare Part A, Part B, Part C, & Part D. Centers for Medicare & Medicaid Services website. https://www.cms.gov/outreach-and-education/outreach/ partnerships/downloads/11315-p.pdf. Updated August 2017. Accessed October 8, 2018. 12. What is a MAC. Centers for Medicare & Medicaid Services website. https://www cms.gov/Medicare/Medicare-Contracting/Medicare-Administrative-Contractors/What-is-a-MAC.html. Updated October 26, 2017. Accessed October 9, 2018.

To find your Medicare Part B or DME MAC jurisdiction, visit the CMS website.



APPENDIX SAMPLE ANNOTATED FORMS

Note: Sample form and annotations are for example only. Providers must contact their patient's health plan representative to confirm required coding and documentation for individual situations.

• Incomplete or invalid information will render form invalid and unable to be processed, causing payment delays

Sample CMS-1500 physician office billing: ELZONRIS INJECTION FOR IV USE


LINE	TITLE	INFO	CODES
19		ld for electronic claims (SV202-2) is limited to 80 character of additional space is needed. Check with the payer	
21	DIAGNOSIS CODE	Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis.	BPDCN ICD-10-CM: C86.4
24	DATES, PROCEDURES	, POINTER, AND MODIFIER	
		Commercial, Medicare, Medicare Advantage, Medicaid fee-for-service HCPCS codes	• J9269 Injection, tagraxofusp-erzs, 10 mcg
24D	PROCEDURES, SERVICES, OR SUPPLIES	CPT - Chemotherapy and complex drug/biologic infusions	 96413 Chemotherapy administration, IV infusion technique, up to 1 hour, single or initial substance or drug 96409 Chemotherapy administration, IV push, single or initial substance or drug
24E	DIAGNOSIS POINTER	Specify diagnosis from Item 21, A-L, relating to each C	PT/HCPCS code listed in Item 24D.
24G	NDC SERVICE UNITS	Plan requires the number of NDC units J9269 injection Specify the appropriate number of service units as des	

HEALTH INSURANCE CLAIM FORM APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12 MEDICARE CHAMPV CHAMPVA GROUP FECA HEALTH PLAN BLK LUNG (ID#) (ID#) (Medicare#) (Medicaid#) (ID#/DoD#) 2. PATIENT'S NAME (Last Name, First Name, Middle Initial) PATIENT'S BIRTH DATE MM DD CCYY 5. PATIENT'S ADDRESS (No., Street) STATE 8. RESERVED FOR NUCC USE ZIP CODE Leave blank TELEPHONE (Include Area Code) 9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) a. OTHER INSURED'S POLICY OR GROUP NUMBER a. EMPLOYMENT? (Current or Previous) i.e., Medigap Policy number Leave blank YES . RESERVED FOR NUCC US OTHER ACCIDENT? Leave blank YES d. INSURANCE PLAN NAME OR PROGRAM NAME COBA Medigap-based identifier
 READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM.

 12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.
 SIGNED Can be "SIGNATURE ON FILE" DATE 14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LM QUAL. MM DD YY QUAL. 17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. Leave blank DN Name 7b. NPI 19 19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) 21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) C86.4 G. L D. PROCEDURES, SERVICES, OR SUPPLIES 24 DATE(S) OF SERVICE 24. B. PLACE OF (Explain Unusual Circumstar YY MM DD MM DD CPT/HCPC 19.20. MM DD YY MM DD YY or 21 ,19269 (24D) 964 3 96409 5 6 25. FEDERAL TAX I.D. NUMBER SSN EIN Number assigned Required field by Provider 1. SIGNATURE OF PHYSICIAN OR SUPPLIER SERVICE FACILITY LOCATION INFORMATION INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) IGNED Required field DATE MWDD/W a. NPI of service facility

NUCC Instruction Manual available at: www.nucc.org

Please see accompanying full Prescribing Information, including Boxed WARNING.



(tagraxofusp-erzs) Injection


APPENDIX SAMPLE ANNOTATED FORMS

Note: Sample form and annotations are for example only. Providers must contact their patient's health plan representative to confirm required coding and documentation for individual situations.

• Incomplete or invalid information will render form invalid and unable to be processed, causing payment delays

Sample CMS-1450/UB-04 hospital outpatient billing: ELZONRIS INJECTION FOR IV USE

LINE	DESCRIPTION		CODES
	REVENUE CODE:	DRUG	Medicare: Revenue code 0636 or 0335 chemotherapy administration IV
42	Corresponding to HCPCS or CPT [®] in FL44	PROCEDURE	Medicare and most payers require a revenue code for each procedure
	Payers vary on revenue code requirements. individual situations.	Please contact the	e patient's health plan to confirm required coding in
43	DESCRIPTION: ELZONRIS INJECTION	PRODUCT	J9269 Injection, tagraxofusp-erzs, 10 mcg
43	FOR IV USE	PROCEDURE	Revenue code: 0636
		PRODUCT	J9269 Injection, tagraxofusp-erzs, 10 mcg Revenue code: 0636
44	PRODUCT AND PROCEDURE: ELZONRIS INJECTION FOR IV USE	PROCEDURE CPT	 CHEMOTHERAPY AND COMPLEX DRUG/BIOLOGIC INFUSIONS 96413 Chemotherapy administration, IV infusion technique, up to 1 hour, single or initial substance/drug 96409 Chemotherapy administration, IV push, single or initial substance/drug Revenue code: 0335
46	NDC Service Units: Plan requires the number the appropriate number of service units as de		9 injection, tagraxofusp-erzs, 10 mcg , used in Item 46. Specify Jual payers. There may be variation.
66	DIAGNOSIS CODE		0
67	ICD-10-CM		C86.4 is the principal diagnosis code for BPDCN
69	ADMIT DX		C86.4
Note: Er	nter code reflecting histology of patient's dise	ase diagnosis.	·
80	Plans are different and some may require an information is provided for timely reimburse		on. Please check with the patient's plan to ensure all required



	ny-ta	0	3a PAT. CNTL #	alpha					ed by pro	
-ate, ID			5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM THROUGH			0234		
					a					Leave blank
a M	ailin	ig addre		-345678	I	MM/DE	1/77	MM	VDD/YY	
1° "1		Junare				с		d		е
20	21	CONDITION 22	I CODES	4 25	26		28	29 ACDT STATE	30	
	21			. 25	20			UNIC		
35 CODE		OCCURRENC FROM	CE SPAN	ROUGH	36 CODE	OCCL FRC	JRREN	CE SPAN	I THROUGH	37
		M/DD/YY		DD/YY		MM/D			VDD/YY	
	39 COE	VALUE DE AM	CODES	4 C	0 ODE	VALUE COD AMOUN	IES T		41 \ CODE	ALUE CODES AMOUNT
a	a 📃									
t										
C										
c	1									
		45 SERV. DATE		SERV. UNITS		47 TOTAL CH	ARGES		48 NON-COV	ERED CHARGES 49
		mm/DD/	77	×						
		MM /DD /	\sim	I						
		mm/DD/	11	1						
		MM/DD/	YY	1						
			· /	I						
I DAT	TE			OTALS						
53 AS	Glava	RIOR PAYMEN		55 EST. AM		IE	56 NP	1 2:	lling oran	ider number
BEN.	19		:	12		:	57			ider number rider number
	29			2º			OTHE			rider number
	39			32			PRV I	0		rider number
			61 GROUP						E GROUP NO	
NUMBE	ER					LOYER NAM				
NUMBE	R					LOYER NAM the insi		A) Priv	mary	
NUMBE	R				(of	the insi	nred		nary condary	
. NUMBE	R				(of (of	the insi	nred nred	l) Se	condary rtiary	
. NUMBE	R				(of (of	the insi the insi	nred nred	l) Se	condary rtiary	58
	R		F		(of (of	the insi the insi	nred nred	l) Se	condary rtiary	
E	ER E	72 ECI	F		40) 40) 40)	the inso the inso the inso P	AVEd AVEd	A) Sei A) Tei	condary rtiary 73	
URE	E	72		ENDING	40) 40) 40)	the insi the insi	AVEd AVEd	a) Se a) Te G uber	condary rtiary 73 QUAL	
	E	72 ECI	LAST		(of (of (of	the inso the inso the inso Provide	AVEd AVEd AVEd	A) Ser A) Ter Mber Fi	condary tiary 73 QUAL RST	
		72 ECI	LAST 77 OPI	ERATING	(of (of (of	the inso the inso the inso P	AVEd AVEd AVEd	A) Ser A) Ter Mber Fl Mber	condary rtiary 73 QUAL RST QUAL	
		72 ECI	LAST 77 OPI LAST	ERATING	(of (of (of NPI MD	the inso the inso the inso Provide	AVEd AVEd AVEd	A) Ser A) Ter Mber Fl Mber	condary tiary 73 oual RST oual RST	
		72 ECI	LAST 77 OPI LAST 78 OTH	ERATING	(of (of (of	the inso the inso the inso Provide	AVEd AVEd AVEd	A) Ser A) Ten Mber Fi Mber	Condary Hiary 73 QUAL RST QUAL RST QUAL	
		72 ECI	LAST 77 OPI LAST 78 OTI LAST	ERATING	(of (of (of NPI MD NPI OPE	the inso the inso the inso Provide	Aved Aved Aved Aved	A) Ser A) Ten Mber Fi Mber	Condary tiary 273 QUAL RST QUAL RST QUAL RST	
		72 ECI	LAST 77 OPI LAST 78 OTH	ERATING	(of (of (of NPI MD	the inso the inso the inso Provide	Aved Aved Aved Aved	A) Ser A) Ter mber Fi mber Fi	Condary Hiary 73 QUAL RST QUAL RST QUAL	

ELZONRIS® (tagraxofusp-erzs) Injection

STEMLINE ARC[®] PROVIDES ACCESS, REIMBURSEMENT SUPPORT, AND CONNECTION TO RESOURCES FOR ELIGIBLE PATIENTS THROUGHOUT TREATMENT WITH ELZONRIS INJECTION FOR IV USE



CCESS

Support for benefits investigation and verification, information on alternate support, and co-pay support for eligible patients*

eimbursement support

Information regarding prior authorization, template letter of medical necessity, appeals of denied claims, and coding & billing support

Connection

ARC Patient Advocates provide an overview of support services, confirm ELZONRIS coverage and financial assistance, and share helpful resources[†]

Stemline ARC is here to help patients, hospitals, and offices alike. We provide:

- Hospital and office access/procurement support
- · Support for prior authorization, medical exceptions, and appeals of denied claims
- Billing and coding guidance, including J-code, NDC, ICD-10, and MS-DRG



Stemline Commercial Co-Pay Program

· Eligible patients may pay as little as \$0 per month supply of ELZONRIS Injection for IV Use



Stemline Patient Assistance Program[‡]

• The Stemline Patient Assistance Program provides ELZONRIS Injection for IV Use to eligible patients who are under- or uninsured. Patients must meet certain criteria to qualify. Call 1-833-4-STEMLINE (1-833-478-3654) for more information



Independent Third-Party Foundations[§]

• Stemline ARC can provide information about independent third-party foundations for eligible patients

For more information about Stemline ARC, call 1-833-4-STEMLINE (1-833-478-3654) from 9:00 AM to 6:00 PM EST, Monday through Friday, or visit ELZONRIS.com/hcp/stemline-arc-summary. Fax completed enrollment form to 1-833-329-7836.

*In order to be eligible for the Stemline Commercial Co-Pay Program, the patient must not have government-funded health insurance (eg, Medicare, Medicaid, or any other federal or state program), must be taking ELZONRIS Injection for IV Use for an FDA-approved indication, and must confirm that they meet all of the eligibility criteria and agree to the rules set forth in the terms and conditions for the program. Patients and healthcare providers are responsible for completing and submitting enrollment forms and coverage or reimbursement documentation. Stemline Therapeutics, Inc. makes no representation or guarantee concerning coverage or reimbursement of any service or item.

⁺ARC Patient Advocates are available to provide resource information and answer questions about financial assistance, insurance benefits, and coverage for ELZONRIS. This supplemental support is not intended to replace discussions between patients and their healthcare providers.

[‡]To be eligible for this program, insured patients must have exhausted all other forms of patient assistance and meet financial criteria. Insured and uninsured patients must also meet certain eligibility criteria.

[§]Stemline Therapeutics, Inc. does not influence or control the operations or eligibility criteria of any independent charitable assistance foundation and cannot guarantee assistance after information has been provided by Stemline ARC. The information is provided as a resource to patients. The foundations that we discuss with patients are not exhaustive or indicative of Stemline Therapeutics, Inc.'s endorsement or financial support. There may be other foundations to support the patient's disease state.





